Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

By David M. Brown, P. Kaiser, M. Michels, G. Soubrane, J. Heier, R. Kim, J. P. Sy, S. Schneider. New England Journal of Medicine, 2006

3,445 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Ten years of anti-vascular endothelial growth factor therapy (2016, methodology): “Ranibizumab was approved for the treatment of AMD in 2006, following the success of the Phase III (ANCHOR) 208,209 and MARINA 207 trials, which showed that ranibizumab not only reduced vision loss but also improved visual acuity.”
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (2012, positive): “5 mg ranibizumab, a humanized onoclonal antibody fragment that blocks VEGF, not nly prevent vision loss in most patients but also lead to ignificant visual gain in approximately one-third.(7,8) The isk of rare but serious adverse events resulting from the ntravitreal procedure, together with the sig”
Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors (2008, background): “PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3554 The involvement of VEGF in AMD has led to the Food and Drug Administration approval of two intraocular anti-VEGF drugs, pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals, NY) [12], an aptamer which was reported to inhibit”